Summary of opinion: Adcetris,brentuximab vedotin, 14/09/2023, Positive

Summary of opinion: Enhertu,trastuzumab deruxtecan, 14/09/2023, Positive

Summary of opinion: Ryeqo,relugolix,estradiol,norethisterone acetate, 14/09/2023, Positive

Summary of opinion: Finlee,dabrafenib, 14/09/2023, Positive

Orphan designation: Dabrafenib mesylate, Treatment of glioma, 09/12/2020, Positive

Summary of opinion: Yorvipath,Palopegteriparatide, 14/09/2023, Positive

Summary of opinion: ZILBRYSQ,Zilucoplan, 14/09/2023, Positive

Human medicines European public assessment report (EPAR): Melatonin Neurim, melatonin, Sleep Initiation and Maintenance Disorders, Date of authorisation: 07/11/2022, Revision: 1, Status: Authorised

Orphan designation: Asunercept, Treatment of myelodysplastic syndromes, 23/08/2017, Positive

Orphan designation: Recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule, Treatment of glioma, 28/01/2010, Positive